Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy

Author:

Magbanua Mark Jesus M1ORCID,Hendrix Laura H2,Hyslop Terry2,Barry William T34,Winer Eric P5,Hudis Clifford6ORCID,Toppmeyer Deborah7,Carey Lisa Anne8,Partridge Ann H5ORCID,Pierga Jean-Yves9,Fehm Tanja10,Vidal-Martínez José11,Mavroudis Dimitrios1213,Garcia-Saenz Jose A14ORCID,Stebbing Justin15,Gazzaniga Paola16,Manso Luis17,Zamarchi Rita18ORCID,Antelo María Luisa19,Mattos-Arruda Leticia De20,Generali Daniele21,Caldas Carlos22ORCID,Munzone Elisabetta23ORCID,Dirix Luc2425,Delson Amy L26,Burstein Harold J5,Qadir Misbah8,Ma Cynthia27,Scott Janet H28,Bidard François-Clément9ORCID,Park John W28,Rugo Hope S28ORCID

Affiliation:

1. Laboratory Medicine, University of California San Francisco, San Francisco, CA, USA

2. Duke Cancer Institute, Duke University, Durham, NC, USA

3. Alliance Statistics and Data Center, Dana-Farber/Partners CancerCare, Boston, MA, USA

4. Rho Inc., Raleigh, NC, USA

5. Dana-Farber/Partners CancerCare, Boston, MA, USA

6. Memorial Sloan Kettering Cancer Center, New York, NY, USA

7. Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA

8. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, USA

9. Department of Medical Oncology, Institut Curie, PSL Research University, Paris, France

10. Department of Gynecology and Obstetrics, Heinrich Heine University Düsseldorf, Düsseldorf, Germany

11. Clinical Laboratory, Hospital Arnau de Vilanova, Valencia, Spain

12. Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece

13. Department of Medical Oncology, University Hospital of Heraklion, Greece

14. DCIBERONC, IdISCC Madrid, Spain

15. Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, UK

16. Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy

17. Hospital 12 de Octubre, Madrid, Spain

18. Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

19. Department of Hematology, Complejo Hospitalario de Navarra, Pamplona, Spain

20. Val d’Hebron Institute of Oncology, Val d’Hebron University Hospital, and Universitat Autònoma de Barcelona, Barcelona, Spain

21. Women Cancer Center, University of Trieste, Trieste, Italy

22. Cancer Research UK Cambridge Institute and Department of Oncology Li Ka Shing Centre, University of Cambridge, Cambridge, UK

23. Division of Medical Senology, European Institute of Oncology, IRCCS, Milano, Italy

24. Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Antwerp, Belgium

25. University of Antwerp, Antwerp, Belgium

26. Breast Science Advocacy Group, University of California San Francisco, San Francisco, CA, USA

27. Washington University School of Medicine, St. Louis, MO, USA

28. Division of Hematology Oncology, University of California San Francisco, San Francisco, CA, USA

Abstract

Abstract Background We examined the prognostic significance of circulating tumor cell (CTC) dynamics during treatment in metastatic breast cancer (MBC) patients receiving first-line chemotherapy. Methods Serial CTC data from 469 patients (2202 samples) were used to build a novel latent mixture model to identify groups with similar CTC trajectory (tCTC) patterns during the course of treatment. Cox regression was used to estimate hazard ratios for progression-free survival (PFS) and overall survival (OS) in groups based on baseline CTCs, combined CTC status at baseline to the end of cycle 1, and tCTC. Akaike information criterion was used to select the model that best predicted PFS and OS. Results Latent mixture modeling revealed 4 distinct tCTC patterns: undetectable CTCs (56.9% ), low (23.7%), intermediate (14.5%), or high (4.9%). Patients with low, intermediate, and high tCTC patterns had statistically significant inferior PFS and OS compared with those with undetectable CTCs (P < .001). Akaike Information Criterion indicated that the tCTC model best predicted PFS and OS compared with baseline CTCs and combined CTC status at baseline to the end of cycle 1 models. Validation studies in an independent cohort of 1856 MBC patients confirmed these findings. Further validation using only a single pretreatment CTC measurement confirmed prognostic performance of the tCTC model. Conclusions We identified 4 novel prognostic groups in MBC based on similarities in tCTC patterns during chemotherapy. Prognostic groups included patients with very poor outcome (intermediate + high CTCs, 19.4%) who could benefit from more effective treatment. Our novel prognostic classification approach may be used for fine-tuning of CTC-based risk stratification strategies to guide future prospective clinical trials in MBC.

Funder

National Cancer Institute

National Institutes of Health

Alliance for Clinical Trials in Oncology

Bristol-Myers

Breast Cancer Research Foundation

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3